Literature DB >> 30405826

Effects of FOXM1 inhibition and ionizing radiation on melanoma cells.

Vivienne S Lee1, Lucinda S McRobb1, Vaughan Moutrie2, Estavam D Santos2, Timothy L Siu1.   

Abstract

Metastatic melanoma can be highly refractory to conventional radiotherapy and chemotherapy but combinatorial-targeted therapeutics are showing greater promise on improving treatment efficacy. Previous studies have shown that knockdown of Forkhead box M1 (FOXM1) can sensitize various tumor types to radiation-induced cell death. The effect of combining radiation with a small molecule FOXM1 inhibitor, Siomycin A, on growth, death and migration of a metastatic melanoma cell line (SK-MEL-28) that overexpresses this pleiotropic cell cycle regulator was investigated. Siomycin A (SIOA) was found to be a strong inducer of apoptosis, and inhibitor of proliferation and migration in a scratch wound assay in this cell line. Induction of apoptosis occurred at concentrations >1 µM in association with reductions in the constitutive FOXM1 and anti-apoptotic B-cell lymphoma 2 protein levels found in these cells. Single doses of ionizing radiation (0-40 Gy) delivered by linear accelerator caused inhibition of growth and migration without significant induction of cell death. Pretreatment with SIOA did not increase the sensitivity of this melanoma cell line to radiation as observed in other tumor types. These data confirm that as a single agent, SIOA is an effective inducer of cell death and inhibitor of migration in metastatic melanoma cells expressing constitutive FOXM1. In combination with radiation, SIOA pre-treatment, however, may not be of added benefit.

Entities:  

Keywords:  FOXM1; Siomycin A; irradiation; melanoma; thiazole antibiotics

Year:  2018        PMID: 30405826      PMCID: PMC6202528          DOI: 10.3892/ol.2018.9482

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  29 in total

Review 1.  The emerging roles of forkhead box (Fox) proteins in cancer.

Authors:  Stephen S Myatt; Eric W-F Lam
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

2.  Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.

Authors:  Bridget N Fahy; Michael G Schlieman; Melinda M Mortenson; Subbulakshmi Virudachalam; Richard J Bold
Journal:  Cancer Chemother Pharmacol       Date:  2005-03-25       Impact factor: 3.333

3.  Central nervous system metastases in malignant melanoma.

Authors:  D E Bullard; E B Cox; H F Seigler
Journal:  Neurosurgery       Date:  1981-01       Impact factor: 4.654

4.  Bcl-2 and Mn-SOD antisense oligodeoxynucleotides and a glutamine-enriched diet facilitate elimination of highly resistant B16 melanoma cells by tumor necrosis factor-alpha and chemotherapy.

Authors:  María Benlloch; Salvador Mena; Paula Ferrer; Elena Obrador; Miguel Asensi; José A Pellicer; Julian Carretero; Angel Ortega; José M Estrela
Journal:  J Biol Chem       Date:  2005-11-01       Impact factor: 5.157

5.  FoxM1, a critical regulator of oxidative stress during oncogenesis.

Authors:  Hyun Jung Park; Janai R Carr; Zebin Wang; Veronique Nogueira; Nissim Hay; Angela L Tyner; Lester F Lau; Robert H Costa; Pradip Raychaudhuri
Journal:  EMBO J       Date:  2009-08-20       Impact factor: 11.598

Review 6.  FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.

Authors:  Inken Wierstra
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

7.  Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

Authors:  Matteo S Carlino; Jason R Todd; Kavitha Gowrishankar; Branka Mijatov; Gulietta M Pupo; Carina Fung; Stephanie Snoyman; Peter Hersey; Georgina V Long; Richard F Kefford; Helen Rizos
Journal:  Mol Oncol       Date:  2014-01-15       Impact factor: 6.603

8.  Determination of cell survival after irradiation via clonogenic assay versus multiple MTT Assay--a comparative study.

Authors:  Karl Buch; Tanja Peters; Thomas Nawroth; Markus Sänger; Heinz Schmidberger; Peter Langguth
Journal:  Radiat Oncol       Date:  2012-01-03       Impact factor: 3.481

9.  Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing.

Authors:  Gulietta M Pupo; Suzanah C Boyd; Carina Fung; Matteo S Carlino; Alexander M Menzies; Bernadette Pedersen; Peter Johansson; Nicholas K Hayward; Richard F Kefford; Richard A Scolyer; Georgina V Long; Helen Rizos
Journal:  Biomark Res       Date:  2017-05-11

10.  FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2.

Authors:  Yeri Lee; Kang Ho Kim; Dong Geon Kim; Hee Jin Cho; Yeonghwan Kim; Jinguen Rheey; Kayoung Shin; Yun Jee Seo; Yeon-Sook Choi; Jung-Il Lee; Jeongwu Lee; Kyeung Min Joo; Do-Hyun Nam
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

View more
  2 in total

1.  Siomycin A induces reactive oxygen species-mediated cytotoxicity in ovarian cancer cells.

Authors:  Xiulan Shao; Fengying Zhang; Xiang Gao; Fengying Xu
Journal:  Oncol Lett       Date:  2021-03-31       Impact factor: 2.967

2.  A combined aging and immune prognostic signature predict prognosis and responsiveness to immunotherapy in melanoma.

Authors:  Wenchang Lv; YuanYuan Zhan; Yufang Tan; Yiping Wu; Hongbo Chen
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.